Shattuck Labs reports Q1 net loss $20.7M; cash $135.5M; clinical milestones on track

Shattuck Labs, Inc.

2023-Q1 EPS reported -$0.49 revenue$57,000

Net loss $20.7M ($0.49 per share) vs $24.5M ($0.58 per share) in Q1 2022.
Cash and investments $135.5M at March 31, 2023, expected to fund operations through year-end 2024.
R&D expenses $16.7M (down from $19.2M); G&A $5.1M (flat YoY).
Complete Phase 1A monotherapy data for SL-172154 in PROC to be presented at ASCO June 2023.
Initial Phase 1B combo data (liposomal doxorubicin) expected mid-2023; mirvetuximab combo trial dosed first patients.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Shattuck Labs, Inc. reported financial results for the quarter ended March 31, 2023.

Period: the quarter ended March 31, 2023
Result: reported results

Exact text from the filing

On May 9, 2023, Shattuck Labs, Inc. issued a press release announcing its financial results for the quarter ended March 31, 2023.

View on SEC.gov

Browse all earnings releases →

Shattuck Labs, Inc. filing history →

Source: SEC EDGAR

accession 0001680367-23-000033

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.